Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01509768 · ClinicalTrials.gov registry record

Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)

A clinical trial of Sanfilippo Syndrome Type B, sponsored by Shire.

Completed
Registry status
19
Enrollment target
4
Study locations

NCT01509768 is a study of Sanfilippo Syndrome Type B that has completed, run by Shire. The registered enrollment target is 19 participants. The trial reports 4 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01509768, a study of Sanfilippo Syndrome Type B, has completed, sponsored by Shire.

COMPLETED
Registry status
19 participants
Enrollment target
4
Study locations

Study Summary

The purpose of this study is to evaluate the natural course of disease progression in Mucopolysaccharidosis Type III (MPS IIIB) patients who are untreated to identify potential surrogate endpoints that may be utilized in future treatment trials of MPS IIIB using predefined assessments including standardized clinical, biochemical, neurocognitive, developmental, and imaging measures.

Conditions Studied

Study Locations (4)

Other

  • Johannes Gutenberg University Medical Center - Mainz
  • Great Ormond Street Hospital for Children - London

California

  • Children's Hospital and Research Center - Oakland

Minnesota

  • University of Minnesota - Minneapolis

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2012-04-09
Est. Completion 2013-10-10

Sponsor

Shire

245 total trials

What the Registry Record Tells You About NCT01509768

The ClinicalTrials.gov registry entry for NCT01509768 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shire, which has 245 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sanfilippo Syndrome Type B appearing as the primary indexed condition, and to 0 interventions.

NCT01509768 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Other, California, Minnesota.

Frequently Asked Questions

What is clinical trial NCT01509768 about?

NCT01509768 is a clinical study titled "Natural History Study of Patients With Mucopolysaccharidosis Type IIIB (MPS IIIB, Sanfilippo Syndrome Type B)". The purpose of this study is to evaluate the natural course of disease progression in Mucopolysaccharidosis Type III (MPS IIIB) patients who are untreated to identify potential surrogate endpoints that may be utilized in future treatment trials of MPS IIIB using predefined assessments including stan...

What is the current status of trial NCT01509768?

This trial is currently completed. The enrollment target is 19 participants. The study started on 2012-04-09. Estimated completion is 2013-10-10.

What conditions does trial NCT01509768 study?

This clinical trial studies the following conditions: Sanfilippo Syndrome Type B.

Who is sponsoring clinical trial NCT01509768?

This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01509768 being conducted?

This trial has 4 study locations across California, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sanfilippo Syndrome Type B

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.